Use of bacteriophage for discovery of therapeutically relevant antibodies against infectious diseases

被引:1
|
作者
Jones, Martina L. [1 ]
机构
[1] Univ Queensland, Natl Biol Facil, ARC Training Ctr Biopharmaceut Innovat, Australian Inst Bioengn & Nanotcchnol, St Lucia, Qld 4072, Australia
关键词
HUMAN SCFV; PHAGE; VIRUS; FRAGMENTS; GENERATION; REPERTOIRE; HENDRA;
D O I
10.1071/MA19007
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Scientists George P Smith and Gregory Winter were recently awarded half of the 2018 Nobel Prize for Chemistry for developing a technology to display exogenous peptides and proteins on the surface of bacteriophage. 'Phage display' has revolutionised the development of monoclonal antibodies, allowing fully human-derived antibodies to be isolated from large antibody libraries. It has been used for the discovery of many blockbuster drugs, including Humira (adalimumab), the highest selling drug yearly since 2012, with US$18.4b in sales globally in 2017(1). Phage display can be used to isolate antibodies to almost any antigen for a wide range of applications including clinical use (for cancer, inflammatory conditions and infectious diseases), diagnostic use or as research tools. The technology is accessible to any laboratory equipped for molecular biology and bacteria culture.
引用
收藏
页码:33 / 36
页数:4
相关论文
共 50 条
  • [1] Rapid discovery and optimization of therapeutic antibodies against emerging infectious diseases
    Rogers, J.
    Schoepp, R. J.
    Schroeder, O.
    Clements, T. L.
    Holland, T. F.
    Li, J. Q.
    Li, J.
    Lewis, L. M.
    Dirmeier, R. P.
    Frey, G. J.
    Tan, X.
    Wong, K.
    Woodnutt, G.
    Keller, M.
    Reed, D. S.
    Kimmel, B. E.
    Tozer, E. C.
    PROTEIN ENGINEERING DESIGN & SELECTION, 2008, 21 (08): : 495 - 505
  • [2] The use of antibodies in the treatment of infectious diseases
    Chan, C. E. Z.
    Chan, A. H. Y.
    Hanson, B. J.
    Ooi, E. E.
    SINGAPORE MEDICAL JOURNAL, 2009, 50 (07) : 663 - 672
  • [3] Drug discovery and the use of computational approaches for infectious diseases
    Marhoefer, Richard J.
    Oellien, Frank
    Selzer, Paul M.
    FUTURE MEDICINAL CHEMISTRY, 2011, 3 (08) : 1011 - 1025
  • [4] Safety and General Considerations for the Use of Antibodies in Infectious Diseases
    Hey, Adam Seidelin
    RECOMBINANT ANTIBODIES FOR INFECTIOUS DISEASES, 2017, 1053 : 265 - 294
  • [5] Gold nanoparticles for preparation of antibodies and vaccines against infectious diseases
    Dykman, Lev A.
    EXPERT REVIEW OF VACCINES, 2020, 19 (05) : 465 - 477
  • [6] Bacteriophage T4 nanoparticles for vaccine delivery against infectious diseases
    Tao, Pan
    Zhu, Jingen
    Mahalingam, Marthandan
    Batra, Himanshu
    Rao, Venigalla B.
    ADVANCED DRUG DELIVERY REVIEWS, 2019, 145 : 57 - 72
  • [7] THE USE OF ANTIIDIOTYPIC ANTIBODIES AS VACCINES AGAINST INFECTIOUS AGENTS
    FINBERG, RW
    ERTL, H
    CRC CRITICAL REVIEWS IN IMMUNOLOGY, 1987, 7 (04): : 269 - 284
  • [8] Bacteriophage therapy of infectious diseases in aquaculture
    Nakai, T
    Park, SC
    RESEARCH IN MICROBIOLOGY, 2002, 153 (01) : 13 - 18
  • [9] Seroprevalence of antibodies against infectious pathogens relevant to pregnancy among healthcare workers
    Wicker, S.
    Friedrichs, I.
    Rabenau, H. F.
    BUNDESGESUNDHEITSBLATT-GESUNDHEITSFORSCHUNG-GESUNDHEITSSCHUTZ, 2012, 55 (08) : 923 - 929
  • [10] On drug discovery against infectious diseases and academic medicinal chemistry contributions
    Janin, Yves L.
    BEILSTEIN JOURNAL OF ORGANIC CHEMISTRY, 2022, 18 : 1355 - 1378